Related Experiment Video
Updated: Aug 17, 2026
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
Proteasome inhibition as a therapeutic strategy for hematologic malignancies
Constantine S Mitsiades1, Nicholas Mitsiades, Teru Hideshima
1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA, USA. Constantine_Mitsiades@dfci.harvard.edu
Abstract:
The ubiquitin-proteasome pathway is a principal intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies since several cell cycle regulators and modulators of apoptosis are degraded through this pathway. The current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the US Food and Drug Administration for the treatment of advanced multiple myeloma, is reviewed. Particular emphasis is placed on the preclinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and an appraisal of possible uses in other hematologic malignancies, such as non-Hodgkin's lymphomas.
Insights
The ubiquitin-proteasome pathway targets cancer by degrading key proteins. Bortezomib, a proteasome inhibitor, is approved for multiple myeloma and shows promise for other blood cancers.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- The ubiquitin-proteasome pathway regulates protein degradation.
- This pathway is crucial for controlling cell cycle and apoptosis.
- Dysregulation of this pathway is implicated in cancer development.
Purpose of the Study:
- To review the current state of proteasome inhibitors in cancer therapy.
- To highlight preclinical data supporting clinical applications.
- To assess the potential of proteasome inhibitors in various hematologic malignancies.
Main Methods:
- Review of preclinical research data.
- Overview of clinical trial outcomes for proteasome inhibitors.
- Appraisal of therapeutic potential in hematologic cancers.
Main Results:
- Bortezomib, a proteasome inhibitor, is approved for advanced multiple myeloma.
- Preclinical data established the foundation for clinical use.
- Proteasome inhibitors demonstrate efficacy in multiple myeloma and potential in other lymphomas.
Conclusions:
- Proteasome inhibitors represent a significant advancement in anticancer therapy.
- Bortezomib's success validates the ubiquitin-proteasome pathway as a therapeutic target.
- Further investigation into proteasome inhibitors for hematologic malignancies is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Inhibitors of Viral Protein Synthesis
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:15Drugs that Stabilize Microtubules